GO:0035733 hepatic stellate cell activation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035733 hepatic stellate cell activation describes the morphological and behavioral transition of hepatic stellate cells (HSCs) from a quiescent, vitamin A-storing state to an activated, myofibroblast-like phenotype in response to cytokines, chemokines, hormones, cellular ligands, or soluble factors.
• Activated HSCs are the principal source of extracellular matrix in liver fibrosis and are central to the progression of metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, and hepatocellular carcinoma [2,6].
• TGF-beta signaling, epigenetic reprogramming, autophagy, and microRNA networks are key regulatory layers controlling HSC activation [3,4,6,7].
• Inflammatory mediators such as PAD4-positive neutrophil-derived NET-DNA and ISG15 deficiency in HSCs can amplify TGF-beta-driven fibrogenesis [7,8].
• Pharmacological inhibition of HSC activation, for example by Esculin via Nrf2/GPX4, reduces CCl4-induced liver fibrosis in preclinical models.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of genes driving HSC activation and fibrosis.
Description
Hepatic stellate cell activation (GO:0035733) is the biological process by which hepatic stellate cells (HSCs) change their morphology or behavior following exposure to a cytokine, chemokine, hormone, cellular ligand, or soluble factor. In the healthy liver, HSCs reside in the space of Disse in a quiescent, vitamin A-storing state; upon chronic injury or metabolic stress, they transdifferentiate into proliferative, contractile, myofibroblast-like cells that deposit excessive extracellular matrix. This transition is now recognized as the central cellular event in liver fibrosis and a major driver of progression toward cirrhosis and hepatocellular carcinoma [2,6]. Because HSC activation integrates signals from injured hepatocytes, immune cells, and the extracellular milieu, it sits at the intersection of inflammation, metabolism, and epigenetic regulation. Recent work has shown that HSC phenotypes in metabolic dysfunction-associated steatohepatitis (MASH) are dynamically regulated and heterogeneous, with distinct subpopulations contributing to fibrosis and inflammation. At the molecular level, activation is accompanied by changes in microRNA networks, DNA methylation, histone modifications, and autophagic flux [3,4,6]. For researchers, GO:0035733 provides a precise ontological anchor for studying fibrosis biology, testing anti-fibrotic compounds, and identifying causal genes. The process is experimentally tractable: HSCs can be isolated and cultured, activated in vitro by TGF-beta or other soluble factors, and modeled in vivo using CCl4 or diet-induced fibrosis [1,5,8]. This article summarizes the definition, mechanism, key genes, disease links, and CRISPR-based research strategies for GO:0035733.
hepatic stellate cell activation At A Glance
| GO ID | GO:0035733 |
|---|---|
| GO term | hepatic stellate cell activation |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Morphological and behavioral transition of hepatic stellate cells to a myofibroblast-like, fibrogenic phenotype in response to soluble mediators |
| Triggering stimuli | Cytokines, chemokines, hormones, cellular ligands, and soluble factors |
| Cellular outcome | Increased proliferation, contractility, extracellular matrix production, and loss of vitamin A storage |
| Disease relevance | Liver fibrosis, MASH, cirrhosis, and hepatocellular carcinoma |
| Research tractability | Modeled in vitro with TGF-beta or other factors and in vivo with CCl4 or diet-induced injury |
What Is GO:0035733?
GO:0035733 hepatic stellate cell activation is defined in QuickGO as a change in the morphology or behavior of a hepatic stellate cell resulting from exposure to a cytokine, chemokine, hormone, cellular ligand, or soluble factor. In practice, this encompasses the transition from a quiescent, lipid- and vitamin A-storing perisinusoidal cell to an activated, proliferative, contractile, and fibrogenic myofibroblast-like cell. The term is a biological process and has no listed synonyms in QuickGO.
Why Is hepatic stellate cell activation Important in Cell Biology?
GO:0035733 is important because activated HSCs are the principal effector cells of liver fibrosis, and their persistent activation drives the progression of chronic liver diseases including MASH, cirrhosis, and hepatocellular carcinoma [2,6]. Understanding the soluble factors, signaling pathways, and epigenetic programs that control this transition is essential for developing anti-fibrotic therapies, and the process is highly amenable to experimental manipulation using cytokines, pharmacological agents, and genetic tools [1,3,5].
• Activated HSCs are the major source of extracellular matrix in liver fibrosis.
• HSC activation is a central event in the progression of metabolic dysfunction-associated steatohepatitis (MASH).
• Epigenetic reprogramming during HSC activation contributes to fibrosis and carcinogenesis.
• MicroRNA networks regulate the balance between HSC quiescence and activation.
• Autophagy in HSCs modulates extracellular vesicle release and fibrosis severity.
• Inflammatory signals such as PAD4-positive neutrophil NET-DNA accelerate HSC activation and MASH fibrosis.
• ISG15 deficiency in HSCs promotes TGF-beta2-induced liver fibrosis.
• Pharmacological activation of Nrf2/GPX4 by Esculin inhibits HSC activation and CCl4-induced fibrosis.
• Mitochondrial and lysosomal dysfunction can directly induce HSC activation and fibrogenesis.
• HSC activation is a tractable target for CRISPR-based functional genomics and anti-fibrotic drug discovery [1,2].
What Happens During hepatic stellate cell activation?
Initiation by soluble mediators
In simple terms: Hepatic stellate cells start changing when they sense signals released by injured liver cells and immune cells.
The process begins when quiescent HSCs are exposed to cytokines, chemokines, hormones, cellular ligands, or soluble factors. In MASH and other chronic liver injuries, these mediators include TGF-beta family ligands and inflammatory cues that reprogram HSC gene expression [2,7]. Neutrophil-derived NET-DNA can also act through TAOK1/MAPK pathways to promote HSC activation. This initiation phase is characterized by early transcriptional changes and loss of the quiescent vitamin A-storing phenotype.
Transcriptional and epigenetic reprogramming
In simple terms: The cell rewrites which genes are switched on or off, locking in the activated state.
Activation involves widespread epigenetic changes, including DNA methylation and histone modifications, that stabilize the myofibroblast-like phenotype. MicroRNAs participate in the interplay between quiescence and activation, fine-tuning the expression of fibrogenic genes. These layers of regulation ensure that once HSCs commit to activation, the phenotype is sustained and responsive to ongoing injury signals [2,6].
Autophagy and vesicle release
In simple terms: The cell's recycling system influences how it communicates with other liver cells.
Autophagy in HSCs can inhibit extracellular vesicle release and thereby attenuate liver fibrosis, indicating that intracellular degradation pathways modulate the activation program. Conversely, mitochondrial and lysosomal dysfunction induced by agents such as CCCP can trigger HSC activation and liver fibrogenesis. These findings link organelle quality control to the morphological and behavioral changes that define GO:0035733 [4,5].
Myofibroblast-like phenotype and matrix deposition
In simple terms: Activated cells become contractile matrix factories that stiffen the liver.
The endpoint of HSC activation is a proliferative, contractile, and fibrogenic myofibroblast-like cell that produces excessive extracellular matrix. This matrix deposition is the histological hallmark of fibrosis and creates a microenvironment that further promotes HSC activation and disease progression [2,6]. In MASH, distinct HSC phenotypes and subpopulations contribute differentially to fibrosis and inflammation.
Resolution and heterogeneity
In simple terms: Not all activated cells behave the same, and some can revert or die.
HSC activation is not always irreversible; depending on the injury context, activated HSCs can undergo apoptosis, senescence, or reversion to a more quiescent-like state. Single-cell and spatial studies have revealed heterogeneity among activated HSCs in MASH, with different subpopulations expressing distinct marker profiles. This heterogeneity has implications for therapeutic targeting and for interpreting experimental models of GO:0035733 [2,6].
Key Genes Involved in GO:0035733 hepatic stellate cell activation
The following genes and proteins have been experimentally implicated in hepatic stellate cell activation (GO:0035733) and its regulation in fibrosis models.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TGFB1 | Master cytokine driving HSC activation and fibrogenesis | Central target for anti-fibrotic intervention and in vitro activation models [2,7] |
| TGFB2 | TGF-beta family ligand promoting HSC activation | Linked to ISG15 deficiency and CREB1 ISGylation in fibrosis |
| CREB1 | Transcription factor counteracted by ISG15 deficiency in HSCs | Modulates TGF-beta2-induced liver fibrosis |
| ISG15 | Ubiquitin-like modifier regulating HSC activation | Deficiency promotes TGF-beta2-induced liver fibrosis |
| Nrf2 (NFE2L2) | Antioxidant transcription factor | Esculin activates Nrf2/GPX4 to inhibit HSC activation |
| GPX4 | Glutathione peroxidase protecting against lipid peroxidation | Part of Nrf2/GPX4 axis inhibiting HSC activation |
| PAD4 (PADI4) | Enzyme mediating neutrophil NET formation | PAD4-positive neutrophils promote HSC activation via NET-DNA/TAOK1/MAPK |
| TAOK1 | Kinase in MAPK signaling downstream of NET-DNA | Mediates neutrophil-driven HSC activation in MASH |
| MAPK pathway components | Stress and inflammatory signaling kinases | Transmit NET-DNA signals to activate HSCs |
| Autophagy-related genes (e.g., ATG family) | Regulate autophagic flux in HSCs | Autophagy inhibits extracellular vesicle release and fibrosis |
| MicroRNAs (e.g., miR-29 family) | Post-transcriptional regulators of HSC quiescence/activation | Modulate the balance between quiescence and activation |
| Epigenetic modifiers (DNMTs, HDACs) | DNA methylation and histone acetylation enzymes | Drive epigenetic reprogramming during HSC activation |
| Mitochondrial regulators | Control mitochondrial function and ROS | CCCP-induced mitochondrial dysfunction activates HSCs |
| Lysosomal regulators | Maintain lysosomal integrity and function | Lysosomal dysfunction contributes to HSC activation |
| Extracellular matrix genes (e.g., COL1A1) | Produce collagen and matrix components | Readout of activated HSC phenotype |
| Inflammatory cytokine genes (e.g., IL-6, TNF) | Amplify inflammatory signaling in the liver | Contribute to HSC activation in MASH [2,8] |
| Vitamin A storage genes | Maintain quiescent HSC lipid phenotype | Loss of expression marks activation |
How Is hepatic stellate cell activation Regulated?
Hepatic stellate cell activation is regulated at multiple levels. TGF-beta signaling is a dominant driver, and its activity can be modulated by ISG15-mediated regulation of CREB1 ISGylation in HSCs. Inflammatory cells, particularly PAD4-positive neutrophils, release NET-DNA that signals through TAOK1/MAPK pathways to promote activation. Epigenetic mechanisms, including DNA methylation and histone modifications, establish and maintain the activated state. MicroRNAs provide an additional layer of post-transcriptional control over the quiescence-to-activation transition. Autophagy and organelle quality control pathways also influence activation, with autophagy inhibiting extracellular vesicle release and fibrosis, while mitochondrial and lysosomal dysfunction can directly trigger activation. Pharmacological modulation of the Nrf2/GPX4 axis can inhibit HSC activation and fibrosis.
hepatic stellate cell activation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFB1 | Liver fibrosis and MASH | TGF-beta-stimulated HSC cultures; CCl4-induced fibrosis in mice [1,2] |
| ISG15 | TGF-beta2-induced liver fibrosis | ISG15 knockout HSCs and fibrosis models |
| PADI4 (PAD4) | MASH fibrosis via neutrophil NETs | PAD4-deficient neutrophils co-cultured with HSCs; MASH diet models |
| NFE2L2 (Nrf2) | Oxidative stress and fibrosis | Nrf2/GPX4 activation by Esculin in CCl4 fibrosis |
| ATG family genes | Autophagy and fibrosis | Autophagy-modulated HSC models and EV release assays |
Liver fibrosis and cirrhosis
Persistent HSC activation leads to excessive extracellular matrix deposition, which is the defining feature of liver fibrosis and a precursor to cirrhosis [2,6]. Experimental models such as CCl4-induced injury demonstrate that inhibiting HSC activation, for example through Nrf2/GPX4 activation by Esculin, reduces fibrosis. Autophagy-mediated attenuation of extracellular vesicle release also reduces fibrosis severity.
Metabolic dysfunction-associated steatohepatitis (MASH)
In MASH, HSC activation is driven by metabolic stress and inflammatory signals, and distinct HSC phenotypes contribute to disease progression. PAD4-positive neutrophils accelerate MASH fibrosis via NET-DNA/TAOK1/MAPK signaling, linking innate immune activation to HSC activation. ISG15 deficiency in HSCs promotes TGF-beta2-induced fibrosis, highlighting interferon-related pathways in MASH pathogenesis.
Hepatocellular carcinoma
Epigenetic mechanisms operative during HSC activation also contribute to liver carcinogenesis, creating a microenvironment that supports tumor development. The fibrotic and inflammatory milieu generated by activated HSCs is permissive for hepatocellular carcinoma progression [2,6].
Drug-induced and toxic liver injury
Mitochondrial and lysosomal dysfunction induced by toxic agents such as CCCP can directly trigger HSC activation and fibrogenesis, providing a mechanistic link between organelle stress and fibrosis. This has implications for understanding drug-induced liver injury and for screening compounds that protect against HSC activation [1,5].
From hepatic stellate cell activation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for HSC activation? | CRISPR knockout in primary HSCs or HSC cell lines followed by TGF-beta stimulation [2,7] |
| Does a specific point mutation alter HSC activation? | CRISPR point-mutation knock-in in HSCs or hepatic cell lines |
| Does a disease-associated variant affect HSC phenotype? | Knock-in of the variant followed by activation assays [2,6] |
| Where and when is a protein expressed during activation? | Tagged knock-in (e.g., fluorescent or epitope tag) in HSCs |
| Does overexpression of a gene drive activation? | CRISPR-mediated overexpression or lentiviral overexpression in HSCs [1,5] |
| Which genes modulate fibrosis in vivo? | CRISPR-edited HSCs transplanted or lineage-traced in CCl4 or MASH models [1,8] |
How to Study the hepatic stellate cell activation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Comparing quiescent and activated HSCs [2,3] |
| Single-cell RNA-seq | HSC heterogeneity and subpopulations | MASH and fibrosis models |
| DNA methylation and histone modification assays | Epigenetic reprogramming | Mechanistic studies of HSC activation |
| MicroRNA profiling | Post-transcriptional regulatory networks | Quiescence-to-activation transition |
| Autophagic flux assays | Autophagy activity | HSC vesicle release and fibrosis |
| Mitochondrial and lysosomal function assays | Organelle integrity and dysfunction | CCCP-induced activation studies |
| Extracellular vesicle isolation | Vesicle release and cargo | HSC communication in fibrosis |
| CCl4 and MASH diet models | In vivo fibrosis and HSC activation | Testing genetic and pharmacological interventions [1,8] |
Transcriptomic profiling of HSC activation
RNA-seq of quiescent versus activated HSCs, including TGF-beta-stimulated cultures, identifies gene expression programs and microRNA networks associated with GO:0035733 [2,3]. Single-cell RNA-seq can resolve HSC heterogeneity in MASH and other fibrosis models.
Epigenomic and microRNA analysis
DNA methylation, histone modification, and microRNA profiling reveal epigenetic mechanisms that stabilize the activated HSC state [3,6]. These approaches help identify regulatory nodes that can be targeted to reverse activation.
Autophagy and extracellular vesicle assays
Autophagic flux measurements and extracellular vesicle isolation quantify how autophagy modulates HSC communication and fibrosis. Mitochondrial and lysosomal function assays can detect organelle dysfunction that triggers activation.
In vivo fibrosis models and pharmacological testing
CCl4-induced and diet-induced fibrosis models are used to test whether genetic or pharmacological interventions alter HSC activation and fibrosis [1,8]. Compounds such as Esculin can be evaluated for their ability to activate Nrf2/GPX4 and inhibit activation.
How CRISPR Can Be Used to Study GO:0035733 hepatic stellate cell activation
Knockout
CRISPR knockout of candidate genes in HSCs or hepatic cell lines can determine whether a gene is required for activation. For example, knocking out ISG15 in HSCs has been used to show that its deficiency promotes TGF-beta2-induced liver fibrosis. Knockout studies of inflammatory pathway components such as PAD4 or TAOK1 can test their role in neutrophil-driven HSC activation.
Point Mutation
CRISPR point-mutation knock-in allows precise testing of disease-associated variants or post-translational modification sites. For instance, mutating ISGylation sites on CREB1 could clarify how ISG15 regulates HSC activation. Point mutations in epigenetic modifiers can reveal residues critical for the activated phenotype.
Knock-in
Knock-in of reporters, tags, or disease variants enables tracking of HSC activation in real time. Tagged knock-in of HSC markers or signaling proteins can be used to monitor expression and localization during activation. Disease-associated variants can be introduced into HSCs to assess their impact on fibrosis-related phenotypes [2,6].
Overexpression
CRISPR-mediated overexpression or lentiviral overexpression of candidate genes can test sufficiency for HSC activation. Overexpressing fibrogenic factors such as TGF-beta family ligands or Nrf2/GPX4 pathway components can modulate activation and fibrosis in vitro and in vivo [1,7]. Overexpression studies complement knockout approaches to establish causality.
How EDITGENE Supports hepatic stellate cell activation Research
Researchers studying hepatic stellate cell activation-related genes often need to determine whether a candidate gene is causally involved in the transition from quiescent to activated HSCs, or whether it merely correlates with fibrosis. Rigorous causal inference requires precise genetic tools that can knockout, mutate, tag, or overexpress the gene of interest in relevant HSC models.
Contact EDITGENE today to design your custom CRISPR model for hepatic stellate cell activation research.
Frequently Asked Questions About hepatic stellate cell activation
What is hepatic stellate cell activation (GO:0035733)?
It is the biological process in which hepatic stellate cells change their morphology or behavior in response to cytokines, chemokines, hormones, cellular ligands, or soluble factors, typically transitioning to a myofibroblast-like, fibrogenic phenotype.
What genes are involved in hepatic stellate cell activation?
Key genes include TGFB1, TGFB2, CREB1, ISG15, NFE2L2 (Nrf2), GPX4, PADI4 (PAD4), TAOK1, autophagy-related genes, and microRNAs such as the miR-29 family [1,3,4,6,7,8].
Why is hepatic stellate cell activation important in liver fibrosis?
Activated HSCs are the principal source of extracellular matrix in liver fibrosis and drive progression to cirrhosis and hepatocellular carcinoma [2,6].
How is hepatic stellate cell activation regulated?
It is regulated by TGF-beta signaling, epigenetic reprogramming, microRNA networks, autophagy, inflammatory mediators such as NET-DNA, and organelle quality control pathways [3,4,5,6,7,8].
What diseases are associated with hepatic stellate cell activation?
It is associated with liver fibrosis, metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, hepatocellular carcinoma, and drug-induced liver injury [1,2,5,6,8].
How do researchers study hepatic stellate cell activation?
Common methods include RNA-seq, single-cell RNA-seq, epigenomic and microRNA profiling, autophagy and extracellular vesicle assays, and in vivo CCl4 or MASH diet models [1,2,3,4,8].
Can CRISPR be used to study hepatic stellate cell activation?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of genes involved in HSC activation and fibrosis [1,2,6,7,8].
What is the role of TGF-beta in hepatic stellate cell activation?
TGF-beta is a master cytokine that drives HSC activation and fibrogenesis, and its signaling can be modulated by factors such as ISG15 and CREB1 [2,7].
How does autophagy affect hepatic stellate cell activation?
Autophagy in HSCs inhibits extracellular vesicle release and attenuates liver fibrosis, while mitochondrial and lysosomal dysfunction can trigger activation [4,5].
What experimental models are used for hepatic stellate cell activation?
Models include TGF-beta-stimulated HSC cultures, CCl4-induced fibrosis, MASH diet models, and CRISPR-edited HSC lines for genetic studies [1,2,7,8].
Conclusion
GO:0035733 hepatic stellate cell activation is a central biological process in liver fibrosis and metabolic liver disease, integrating cytokine, inflammatory, epigenetic, and organelle-derived signals. The process is experimentally tractable through in vitro activation assays, in vivo fibrosis models, and CRISPR-based genetic tools [1,2,4,5,7,8]. Understanding the genes and regulatory layers that control HSC activation can guide the development of anti-fibrotic therapies and improve the interpretation of preclinical models. Continued research using knockout, point-mutation, knock-in, overexpression, and library screening approaches will clarify which molecular nodes are causal and which are most suitable for therapeutic targeting [2,6,7,8].
References
- 1. Xu S et al.. 2024. Esculin inhibits hepatic stellate cell activation and CCl(4)-induced liver fibrosis by activating the Nrf2/GPX4 signaling pathway.. Phytomedicine 128:155465 PMID: 38471319
- 2. Kisseleva T et al.. 2025. Regulation of Hepatic Stellate Cell Phenotypes in Metabolic Dysfunction-Associated Steatohepatitis.. Gastroenterology 169(5):797-812 PMID: 40120772
- 3. Ezhilarasan D. 2020. MicroRNA interplay between hepatic stellate cell quiescence and activation.. Eur J Pharmacol 885:173507 PMID: 32858048
- 4. Gao J et al.. 2020. Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis.. J Hepatol 73(5):1144-1154 PMID: 32389810
- 5. Lee JH et al.. 2024. CCCP induces hepatic stellate cell activation and liver fibrogenesis via mitochondrial and lysosomal dysfunction.. Free Radic Biol Med 225:181-192 PMID: 39370054
- 6. Barcena-Varela M et al.. 2019. Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis.. Int J Mol Sci 20(10) PMID: 31117267
- 7. Yuan Y et al.. 2026. ISG15 deficiency in hepatic stellate cells promotes TGFβ2-induced liver fibrosis by counteracting CREB1 ISGylation.. Gut 75(6):1186-1200 PMID: 40819890
- 8. Shen J et al.. 2026. PAD4+ neutrophils promote hepatic stellate cell activation and accelerate MASH fibrosis progression viaNET-DNA/TAOK1/MAPK pathways.. JCI Insight 11(1) PMID: 41480748
